A Pan-cancer Analysis of MARCH8: Molecular Characteristics, Clinical Relevance, and Immuno-oncology Features

Overview

Journal Cancer Biol Ther

Date 2025 Jan 30

PMID 39881438

Authors

Zihan Quan

Songqing Fan

Hongmei Zheng

Yue Ning

Yang Yang

Affiliations

Soon will be listed here.

Abstract

Membrane-associated RING-CH8 (MARCH8) is a member of the recently discovered MARCH family of ubiquitin ligases. MARCH8 has been shown to participate in immune responses. However, the role of MARCH8 in prognosis and immunology in human cancers remains largely unknown. The expression of MARCH8 protein was detected via immunohistochemistry in non-small cell lung cancer (NSCLC) and non-cancerous lung tissues. The study investigated the role of MARCH8 in tumor immunity through pan-cancer analysis of multiple databases. MARCH8 genetic alternations and expression were explored with the cBioPortal, GTEx, and TCGA databases. We investigated the role of MARCH8 expression in clinical relevance, prognosis, tumor immune microenvironment, immune checkpoint (ICP) with a series of bioinformatics tools and methods, such as TISIDB database, ESTIMATE, and CIBERSORT method. MARCH8 expression showed cancer-specific dysregulation and was associated with the prognosis of patients in various cancers. MARCH8 was related to the tumor microenvironment and participated in tumor immune regulation. Furthermore, low expression of MARCH8 was associated with poor prognosis and might serve as an independent prognostic biomarker for NSCLC patients. The comprehensive pan-cancer analysis revealed the potential of MARCH8 in tumor-targeted therapy, and suggested MARCH8 as a promising prognostic and immunological pan-cancer biomarker.

References

van de Kooij B, Verbrugge I, de Vries E, Gijsen M, Montserrat V, Maas C . Ubiquitination by the membrane-associated RING-CH-8 (MARCH-8) ligase controls steady-state cell surface expression of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) receptor 1. J Biol Chem. 2013; 288(9):6617-28. PMC: 3585101. DOI: 10.1074/jbc.M112.448209. View

Singh S, Saraya A, Das P, Sharma R . Increased expression of MARCH8, an E3 ubiquitin ligase, is associated with growth of esophageal tumor. Cancer Cell Int. 2017; 17:116. PMC: 5715508. DOI: 10.1186/s12935-017-0490-y. View

Wen Q, Wang W, Chu S, Luo J, Chen L, Xie G . Flot-2 Expression Correlates with EGFR Levels and Poor Prognosis in Surgically Resected Non-Small Cell Lung Cancer. PLoS One. 2015; 10(7):e0132190. PMC: 4498790. DOI: 10.1371/journal.pone.0132190. View

Detterbeck F, Boffa D, Kim A, Tanoue L . The Eighth Edition Lung Cancer Stage Classification. Chest. 2016; 151(1):193-203. DOI: 10.1016/j.chest.2016.10.010. View

Fujita Y, Tinoco R, Li Y, Senft D, Ronai Z . Ubiquitin Ligases in Cancer Immunotherapy - Balancing Antitumor and Autoimmunity. Trends Mol Med. 2019; 25(5):428-443. PMC: 6488401. DOI: 10.1016/j.molmed.2019.02.002. View

Ru B, Wong C, Tong Y, Zhong J, Zhong S, Wu W . TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019; 35(20):4200-4202. DOI: 10.1093/bioinformatics/btz210. View

Morrow J, Lin H, Sun S, Zhang S . Targeting ubiquitination for cancer therapies. Future Med Chem. 2015; 7(17):2333-50. PMC: 4976843. DOI: 10.4155/fmc.15.148. View

Thorsson V, Gibbs D, Brown S, Wolf D, Bortone D, Yang T . The Immune Landscape of Cancer. Immunity. 2018; 48(4):812-830.e14. PMC: 5982584. DOI: 10.1016/j.immuni.2018.03.023. View

Jahnke M, Trowsdale J, Kelly A . Ubiquitination of HLA-DO by MARCH family E3 ligases. Eur J Immunol. 2013; 43(5):1153-61. PMC: 3655539. DOI: 10.1002/eji.201243043. View

10.

Fan J, Tian L, Li M, Huang S, Zhang J, Zhao B . MARCH8 is associated with poor prognosis in non-small cell lung cancers patients. Oncotarget. 2018; 8(64):108238-108248. PMC: 5746139. DOI: 10.18632/oncotarget.22602. View

11.

Gao J, Yang Y, Qiu R, Zhang K, Teng X, Liu R . Proteomic analysis of the OGT interactome: novel links to epithelial-mesenchymal transition and metastasis of cervical cancer. Carcinogenesis. 2018; 39(10):1222-1234. PMC: 6175026. DOI: 10.1093/carcin/bgy097. View

12.

Chen W, Patel D, Jia Y, Yu Z, Liu X, Shi H . MARCH8 Suppresses Tumor Metastasis and Mediates Degradation of STAT3 and CD44 in Breast Cancer Cells. Cancers (Basel). 2021; 13(11). PMC: 8196951. DOI: 10.3390/cancers13112550. View

13.

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

14.

Zheng C . The emerging roles of the MARCH ligases in antiviral innate immunity. Int J Biol Macromol. 2021; 171:423-427. DOI: 10.1016/j.ijbiomac.2020.12.207. View

15.

Zhang Y, Parmigiani G, Johnson W . : batch effect adjustment for RNA-seq count data. NAR Genom Bioinform. 2020; 2(3):lqaa078. PMC: 7518324. DOI: 10.1093/nargab/lqaa078. View

16.

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

17.

Wang D, Ma L, Wang B, Liu J, Wei W . E3 ubiquitin ligases in cancer and implications for therapies. Cancer Metastasis Rev. 2017; 36(4):683-702. DOI: 10.1007/s10555-017-9703-z. View

18.

Lin H, Li S, Shu H . The Membrane-Associated MARCH E3 Ligase Family: Emerging Roles in Immune Regulation. Front Immunol. 2019; 10:1751. PMC: 6669941. DOI: 10.3389/fimmu.2019.01751. View

19.

Bulatov E, Valiullina A, Sayarova R, Rizvanov A . Promising new therapeutic targets for regulation of inflammation and immunity: RING-type E3 ubiquitin ligases. Immunol Lett. 2018; 202:44-51. DOI: 10.1016/j.imlet.2018.08.001. View

20.

Bauer J, Bakke O, Morth J . Overview of the membrane-associated RING-CH (MARCH) E3 ligase family. N Biotechnol. 2016; 38(Pt A):7-15. DOI: 10.1016/j.nbt.2016.12.002. View